0001104659-23-061465.txt : 20230516 0001104659-23-061465.hdr.sgml : 20230516 20230516170943 ACCESSION NUMBER: 0001104659-23-061465 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230512 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230516 DATE AS OF CHANGE: 20230516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 23928590 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 8-K 1 tm2315929d1_8k.htm FORM 8-K
0001590560 false 00-0000000 0001590560 2023-05-12 2023-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):   May 12, 2023

 

uniQure N.V.

(Exact Name of Registrant as Specified in Charter)

 

The Netherlands   001-36294   N/A
(State or Other
Jurisdiction of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

Paasheuvelweg 25a,
1105 BP Amsterdam, The Netherlands		   N/A
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +31-20-566-7394

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:

Ordinary Shares, par value €0.05 per share

   QURE   The Nasdaq Stock Market LLC
The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

Royalty Purchase Agreement

 

On May 12, 2023, uniQure biopharma BV, a wholly-owned subsidiary of uniQure N.V., (the “Company”) entered into a royalty purchase agreement (the “Purchase Agreement”) with HemB SPV, L.P. (“Purchaser”) for the sale of a portion of the royalty rights due to the Company from CSL Behring LLC (“CSL Behring”) under the commercialization and license agreement between the Company and CSL Behring dated as of June 24, 2020 (the “Commercialization and License Agreement”), from the net sales of HEMGENIX® (the “Product”).

 

Under the terms of the Purchase Agreement, the Company will receive an upfront cash payment of $375 million in exchange for the lowest royalty tier on CSL Behring’s worldwide net sales of the Product. The Company is also eligible to receive an additional $25 million milestone payment under the Purchase Agreement if 2024 net sales of the Product exceed a pre-specified threshold. The Purchaser will receive up to 1.85 times the purchase price (which includes the upfront payment and, if paid, the $25 million milestone payment) until June 30, 2032 or, if such cap is not met by June 30, 2032, up to 2.25 times the purchase price through December 31, 2038. If 2024 net sales do not exceed a pre-specified threshold, the Company will be obligated to pay $25 million to the Purchaser but only to the extent the Company achieves a future sales milestone under the Commercialization and License Agreement. If such milestone payment is not due from CSL Behring, the Company is not obligated to pay any amounts to the Purchaser.

 

The Company will retain the rights to all other royalties, as well as contractual milestones totaling up to $1.5 billion, under the terms of the Commercialization and License Agreement.

 

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2023.

 

Hercules Amendment

 

In connection with the execution of the Purchase Agreement, the Company entered into Amendment No. 1 (the “Amendment”) to the Third Amended and Restated Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) in its capacity as administrative agent and collateral agent for itself and the other financial institutions or entities party thereto as lenders (the “Lenders”).

 

The Amendment amends the terms of the Loan Agreement, which was entered into on December 15, 2021, by and among the Company, Hercules, the Lenders and certain other parties signatory thereto. Specifically, the amendment provides that the transactions contemplated by the Purchase Agreement are a Permitted Royalty Transaction (as defined in the Loan Agreement), and contains a consent by Hercules and the Lenders to certain arrangements agreed upon between the Company and the Purchaser in the Purchase Agreement. Additionally, the maturity date and the interest-only period of the Loan Agreement was extended to January 5, 2027. Finally, the Company, Hercules and the Lenders agreed to a $1.25 million fee payable by the Company at the earlier of the January 5, 2027 maturity date, the date the Company prepays the outstanding secured obligations under the Loan Agreement, and the date that the secured obligations under the Loan Agreement become due and payable.

 

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2023.

 

2

 

 

Item 2.03Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant

 

The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the financial obligations of the Company under the Purchase Agreement and the Loan Agreement, as amended by the Amendment, is incorporated into this Item 2.03 by reference.

 

Item 8.01Other Events.

 

On May 15, 2023, the Company issued a press release entitled “uniQure Announces Sale of its Royalty Interest in CSL Behring’s HEMGENIX® for Up To $400 Million Cash to HealthCare Royalty and Sagard Healthcare Partners.” The full text of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d) The following exhibits are being filed herewith:

 

99.1 Press Release dated May 15, 2023, entitled “uniQure Announces Sale of its Royalty Interest in CSL Behring’s HEMGENIX® for Up To $400 Million Cash to HealthCare Royalty and Sagard Healthcare Partners”
   
104 Cover Page formatted in Inline XBRL.

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UNIQURE N.V.
   
Date: May 16, 2023 By: /s/ David Cerveny
    David Cerveny
    Chief Legal Officer

 

4

 

 

EXHIBIT INDEX

 

Exhibit
No.		   Description
     
99.1   Press Release dated May 15, 2023, entitled “uniQure Announces Sale of its Royalty Interest in CSL Behring’s HEMGENIX® for Up To $400 Million Cash to HealthCare Royalty and Sagard Healthcare Partners”
     
104   Cover Page formatted in Inline XBRL.

 

5

 

 EX-99.1 2 tm2315929d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

uniQure Announces Sale of Royalty Interest in HEMGENIX®
for Up To $400 Million

 

~ uniQure to receive $375 million upfront cash payment ~

 

~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an interest in HEMGENIX® royalties ~

 

~ Capped royalty financing provides uniQure non-equity-dilutive capital to advance its broad gene therapy pipeline, including AMT-130 for Huntington’s disease ~

 

Lexington, MA and Amsterdam, the Netherlands, May 15, 2023 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX® (etranacogene dezaparvovec-drbl) to HealthCare Royalty (HCRx) and Sagard Healthcare for a gross purchase price of up to $400 million in cash.

 

“This attractive financing provides uniQure with immediate, non-equity-dilutive capital to continue to invest in our AAV gene therapy pipeline and platform and to advance potentially breakthrough gene therapies for patients, including AMT-130 in Huntington’s disease, AMT-260 for refractory temporal lobe epilepsy, AMT-162 for SOD-1 ALS and other product candidates,” stated Matt Kapusta, chief executive officer of uniQure. “The partial monetization of this royalty stream validates the significant potential of HEMGENIX® global sales while substantially reducing commercialization risk for uniQure. We are pleased to reach this agreement with HealthCare Royalty and Sagard Healthcare, each of whom is a recognized leader in funding innovation across life sciences, and look forward to furthering our opportunities for growth and value creation.”

 

Under the terms of the agreement, uniQure will receive an upfront cash payment of $375 million in exchange for the lowest royalty tier on CSL Behring’s worldwide net sales of HEMGENIX® up to 1.85 times the purchase price until June 30, 2032 or, if such cap is not met by June 30, 2032, up to 2.25x the purchase price through December 31, 2038.

 

uniQure also is eligible to receive an additional $25 million milestone payment if 2024 net sales of HEMGENIX® exceed a pre-specified threshold. uniQure will retain the rights to all other royalties under its existing Commercialization and License Agreement with CSL Behring, as well as contractual milestones totaling up to $1.5 billion, including the $100 million milestone for the first U.S. product sale and the $75 million milestone for the first product sale in one of five major European countries if achieved prior to July 2, 2023. The transaction is expected to close no later than 15 business days from signing.

 

Clarke B. Futch, Chairman and Chief Executive Officer of HCRx, stated, “We believe that real innovation is the lifeblood of the biotechnology industry, and it’s a rare opportunity to be part of a true first, with HEMGENIX® being the first gene therapy approved for adults with hemophilia B. We are pleased to be able to provide uniQure with the opportunity to immediately monetize their royalty asset to allow them to continue to develop their innovative gene therapy programs.”

 

“Sagard is excited to complete this transaction and support uniQure with its mission to develop one-time, transformative gene therapies for patients in need,“ said David MacNaughtan, Partner and Head of Sagard Healthcare. “Sagard’s investment reflects our confidence in the commercial prospects of HEMGENIX® which is marketed by CSL Behring.”

 

 

 

 

uniQure led the multi-year development of HEMGENIX® and completed an exclusive global license and commercialization agreement with CSL Behring in May 2021. HEMGENIX® is approved for the treatment of hemophilia B in the U.S., Europe and United Kingdom. CSL Behring also is pursuing registration in additional countries.

 

uniQure expects the transaction will extend its cash runway into the second quarter of 2026, assuming receipt of the contractual milestone payment for the first sale of HEMGENIX® in the U.S.

 

Moelis & Company LLC acted as financial advisor to uniQure in this transaction and Ropes & Gray, LLP acted as legal advisor.

 

HCRx was represented in the transaction by Sidley Austin, LP.

 

Sagard was represented in the transaction by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

 

About HEMGENIX®

 

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

 

HEMGENIX® is a registered trademark of CSL Behring.

 

About uniQure

 

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represents a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology platform to advance a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com

 

About HealthCare Royalty

 

HCRx is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has $6.3 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston and London. For more information, visit www.healthcareroyalty.com. HEALTHCARE ROYALTY® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.

 

About Sagard Healthcare

 

Sagard Healthcare is Sagard’s biopharmaceutical royalties investment strategy, investing in royalties and credit backed by approved and commercial biopharmaceutical products, diagnostics and medical devices. Sagard is a multi-strategy alternative investment asset management firm with more than $13 billion under management and professionals located in Canada, the U.S. and Europe. We invest in venture capital, private equity, private credit, real estate and royalties. We deliver flexible capital, an entrepreneurial culture, and a global network of investors, commercial partners, advisors, and value creation experts. Our dynamic and supportive ecosystem gives our partners the advantage they need to learn, grow and win at every stage. Sagard also engages in private wealth management and new venture creation.

 

 

 

 

uniQure Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements about whether HEMGENIX® will be a commercial success. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the regulatory approval and commercial launch of HEMGENIX®, our clinical trial for Huntington’s disease, the impact of financial and geopolitical events on our Company and the wider economy and health care system, our Commercialization and License Agreement with CSL Behring, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company’s periodic securities filings, including its Annual Report on Form 10-K filed February 27, 2023 and its Quarterly Report on Form 10-Q filed May 9, 2023. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

 

uniQure Contacts:    
     
FOR INVESTORS:   FOR MEDIA:
     
Maria E. Cantor Chiara Russo Tom Malone
Direct: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558
Mobile: 617-680-9452 Mobile: 617-306-9137 Mobile:339-223-8541
m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com

 

 

 EX-101.SCH 3 qure-20230512.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 qure-20230512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 qure-20230512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2315929d1_ex99-1img001.jpg GRAPHIC begin 644 tm2315929d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 12, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2023
Entity File Number 001-36294
Entity Registrant Name uniQure N.V.
Entity Central Index Key 0001590560
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code P7
Entity Address, Address Line One Paasheuvelweg 25a
Entity Address, City or Town Amsterdam
Entity Address, Country NL
Entity Address, Postal Zip Code 1105 BP
City Area Code +31
Local Phone Number 20-566-7394
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, par value €0.05 per share
Trading Symbol QURE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2315929d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001590560 2023-05-12 2023-05-12 iso4217:USD shares iso4217:USD shares 0001590560 false 00-0000000 8-K 2023-05-12 uniQure N.V. P7 001-36294 Paasheuvelweg 25a 1105 BP Amsterdam NL +31 20-566-7394 false false false false Ordinary Shares, par value €0.05 per share QURE NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://uniqure.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2315929d1_8k.htm qure-20230512.xsd qure-20230512_lab.xml qure-20230512_pre.xml tm2315929d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2315929d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2315929d1_8k.htm" ] }, "labelLink": { "local": [ "qure-20230512_lab.xml" ] }, "presentationLink": { "local": [ "qure-20230512_pre.xml" ] }, "schema": { "local": [ "qure-20230512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "qure", "nsuri": "http://uniqure.com/20230512", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315929d1_8k.htm", "contextRef": "From2023-05-12to2023-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://uniqure.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315929d1_8k.htm", "contextRef": "From2023-05-12to2023-05-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://uniqure.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-061465-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-061465-xbrl.zip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